nodes	percent_of_prediction	percent_of_DWPC	metapath
Tyloxapol—LPL—dermis—psoriasis	0.505	0.91	CbGeAlD
Tyloxapol—LPL—Composition of Lipid Particles—APOE—psoriasis	0.0684	0.154	CbGpPWpGaD
Tyloxapol—LPL—tendon—psoriasis	0.0501	0.0902	CbGeAlD
Tyloxapol—LPL—Chylomicron-mediated lipid transport—APOE—psoriasis	0.0411	0.0925	CbGpPWpGaD
Tyloxapol—LPL—Statin Pathway—APOE—psoriasis	0.0268	0.0603	CbGpPWpGaD
Tyloxapol—LPL—Lipoprotein metabolism—APOE—psoriasis	0.0261	0.0587	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.0257	0.0578	CbGpPWpGaD
Tyloxapol—LPL—Retinoid metabolism and transport—APOE—psoriasis	0.0203	0.0457	CbGpPWpGaD
Tyloxapol—LPL—Lipid and lipoprotein metabolism—APOE—psoriasis	0.0174	0.039	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.0123	0.0276	CbGpPWpGaD
Tyloxapol—LPL—Alzheimers Disease—APOE—psoriasis	0.012	0.0271	CbGpPWpGaD
Tyloxapol—LPL—SREBP signalling—PPARG—psoriasis	0.0117	0.0263	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.011	0.0248	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—SOCS1—psoriasis	0.0109	0.0246	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	0.0107	0.0241	CbGpPWpGaD
Tyloxapol—LPL—Diseases associated with visual transduction—APOE—psoriasis	0.0104	0.0233	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.01	0.0225	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.00858	0.0193	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—LEP—psoriasis	0.00808	0.0182	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	0.00731	0.0164	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—PPARG—psoriasis	0.00704	0.0158	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—CARM1—psoriasis	0.00581	0.0131	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	0.00568	0.0128	CbGpPWpGaD
Tyloxapol—LPL—Alzheimers Disease—TNF—psoriasis	0.00557	0.0125	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NDUFA5—psoriasis	0.00557	0.0125	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.00519	0.0117	CbGpPWpGaD
Tyloxapol—LPL—Alzheimers Disease—TP53—psoriasis	0.00491	0.011	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP2S1—psoriasis	0.00473	0.0106	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HCAR2—psoriasis	0.00438	0.00984	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—STAT3—psoriasis	0.00432	0.00971	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TAGAP—psoriasis	0.00379	0.00853	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—TNF—psoriasis	0.00374	0.0084	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—IL6—psoriasis	0.00302	0.00678	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—LEP—psoriasis	0.00278	0.00624	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.00248	0.00557	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—PPARG—psoriasis	0.00242	0.00544	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CARM1—psoriasis	0.00231	0.0052	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCL20—psoriasis	0.00227	0.00511	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.00216	0.00486	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—TYK2—psoriasis	0.00212	0.00476	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—NFKB1—psoriasis	0.00165	0.00371	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—VEGFA—psoriasis	0.0015	0.00337	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—STAT3—psoriasis	0.00148	0.00334	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CAT—psoriasis	0.00142	0.0032	CbGpPWpGaD
Tyloxapol—LPL—Disease—HLA-A—psoriasis	0.00141	0.00318	CbGpPWpGaD
Tyloxapol—LPL—Disease—APOE—psoriasis	0.00132	0.00296	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—TNF—psoriasis	0.00128	0.00289	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SOCS1—psoriasis	0.00125	0.00281	CbGpPWpGaD
Tyloxapol—LPL—Disease—NOS2—psoriasis	0.00123	0.00276	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—APOE—psoriasis	0.0011	0.00248	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—IL6—psoriasis	0.00104	0.00233	CbGpPWpGaD
Tyloxapol—LPL—Disease—TYK2—psoriasis	0.00101	0.00226	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PPARG—psoriasis	0.000962	0.00216	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—LEP—psoriasis	0.000924	0.00208	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APOE—psoriasis	0.000924	0.00208	CbGpPWpGaD
Tyloxapol—LPL—Disease—CD4—psoriasis	0.00091	0.00205	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NFKBIA—psoriasis	0.000861	0.00193	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TYK2—psoriasis	0.000705	0.00158	CbGpPWpGaD
Tyloxapol—LPL—Disease—STAT3—psoriasis	0.000705	0.00158	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL8—psoriasis	0.000614	0.00138	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—JUN—psoriasis	0.000571	0.00128	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NFKB1—psoriasis	0.000549	0.00123	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—VEGFA—psoriasis	0.000498	0.00112	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—STAT3—psoriasis	0.000494	0.00111	CbGpPWpGaD
Tyloxapol—LPL—Disease—IL6—psoriasis	0.000492	0.00111	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TP53—psoriasis	0.000377	0.000847	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IL6—psoriasis	0.000345	0.000775	CbGpPWpGaD
